{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:58:17Z","timestamp":1792634297171,"version":"4.5.0"},"reference-count":88,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"<jats:p>Recent studies on molecular pathways have elucidated novel therapeutic approaches in inflammatory and autoimmune skin disorders. Specifically, the dysregulation of the Janus kinase signal transducer and activator of transcription (JAK-STAT) cascade plays a central role in the pathogenesis of many skin conditions. JAK inhibitors, with their ability to selectively target immune responses, are potential treatment options. Using the National Library of Medicine, we provide a comprehensive review of the use of United States Food and Drug Administration (FDA)-approved and emerging JAK or tyrosine kinase 2 (TYK2) inhibitors in a wide range of dermatologic conditions, including psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. In patients with psoriasis, oral deucravacitinib (TYK2 inhibitor) has been approved as a once-daily therapy with demonstrated superiority and efficacy over apremilast and placebo and tolerable safety profiles. In patients with vitiligo, topical ruxolitinib (JAK1 inhibitor) is approved as a twice-daily treatment for repigmentation. The efficacy of several other JAK inhibitors has also been demonstrated in several clinical trials and case studies for systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease. Further investigations with long-term clinical trials are necessary to confirm their utility in treatment and safety for these diseases.<\/jats:p>","DOI":"10.25259\/ijdvl_15_2023","type":"journal-article","created":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T07:04:40Z","timestamp":1694243080000},"page":"30-40","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease"],"prefix":"10.25259","volume":"90","author":[{"given":"Margaret Y","family":"Huang","sequence":"first","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Keck School of Medicine, University of Southern California, Los Angeles, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2023,9,5]]},"reference":[{"key":"10.25259\/IJDVL_15_2023\/ref-2","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/eji.201646680","article-title":"Targeting JAK\/STAT signaling in inflammatory skin diseases with small molecule inhibitors","volume":"47","author":"Welsch","year":"2017","journal-title":"Eur J Immunol"},{"key":"10.25259\/IJDVL_15_2023\/ref-3","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: The promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1111\/ced.12273","article-title":"An insight into JAK-STAT signalling in dermatology","volume":"39","author":"Palanivel","year":"2014","journal-title":"Clin Exp Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-5","doi-asserted-by":"publisher","first-page":"e0164080","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_15_2023\/ref-6","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: A systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-7","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: Part I","volume":"86","author":"Chapman","year":"2022","journal-title":"A comprehensive review. J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-8","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.jaad.2021.07.002","article-title":"Janus kinase inhibitors in dermatology: Part II","volume":"86","author":"Chapman","year":"2022","journal-title":"A comprehensive review. J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-9","doi-asserted-by":"publisher","first-page":"e15636","DOI":"10.1111\/dth.15636","article-title":"Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis","volume":"35","author":"Wan","year":"2022","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_15_2023\/ref-10","doi-asserted-by":"publisher","first-page":"283617","DOI":"10.1155\/2014\/283617","article-title":"JAK inhibitors: treatment efficacy and safety profile in patients with psoriasis","volume":"2014","author":"Hsu","year":"2014","journal-title":"J Immunol Res"},{"key":"10.25259\/IJDVL_15_2023\/ref-11","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2012.03.013","article-title":"The JAK-STAT pathway at twenty","volume":"36","author":"Stark","year":"2012","journal-title":"Immunity"},{"key":"10.25259\/IJDVL_15_2023\/ref-12","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.cytogfr.2010.10.006","article-title":"Signal transduction pathways and transcriptional regulation in Th17 cell differentiation","volume":"21","author":"Hirahara","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.25259\/IJDVL_15_2023\/ref-13","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1056\/NEJMra0804595","article-title":"Mechanisms of disease: psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.25259\/IJDVL_15_2023\/ref-14","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nm0307-242","article-title":"Cracking the cytokine code in psoriasis","volume":"13","author":"Nickoloff","year":"2007","journal-title":"Nature Medicine"},{"key":"10.25259\/IJDVL_15_2023\/ref-15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3390\/ijms19010171","article-title":"Psoriasis: A STAT3-Centric View","volume":"19","author":"Calautti","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.25259\/IJDVL_15_2023\/ref-16","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.2147\/JIR.S380686","article-title":"TYK2 in immune responses and treatment of psoriasis","volume":"15","author":"Shang","year":"2022","journal-title":"J Inflamm Res"},{"key":"10.25259\/IJDVL_15_2023\/ref-17","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: Focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_15_2023\/ref-18","doi-asserted-by":"publisher","first-page":"S0190","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial","author":"Armstrong","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-19","doi-asserted-by":"publisher","first-page":"S0190","DOI":"10.1016\/j.jaad.2022.07.002","article-title":"Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 POETYK PSO-2 trial","author":"Strober","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-20","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1136\/annrheumdis-2021-221664","article-title":"Efficacy and safety of selective TYK2 inhibitor, deucravacitinib, in a phase II trial in psoriatic arthritis","volume":"81","author":"Mease","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_15_2023\/ref-25","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-26","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomized non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_15_2023\/ref-27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1111\/bjd.13551","article-title":"Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial","volume":"172","author":"Bissonnette","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-28","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jdermsci.2017.05.004","article-title":"The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study","volume":"88","author":"Zhang","year":"2017","journal-title":"J Dermatol Sci"},{"key":"10.25259\/IJDVL_15_2023\/ref-29","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2017.01.053","article-title":"Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis","volume":"77","author":"Merola","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/PTT.S161453","article-title":"Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives","volume":"9","author":"Ly","year":"2019","journal-title":"Psoriasis (Auckl)"},{"key":"10.25259\/IJDVL_15_2023\/ref-31","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-33","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.adengl.2013.03.002","article-title":"Tofacitinib and other kinase inhibitors in the treatment of psoriasis","volume":"104","author":"Ortiz-Ibanez","year":"2013","journal-title":"Actas Dermo-Sifiliogr\u00e1ficas"},{"key":"10.25259\/IJDVL_15_2023\/ref-34","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-36","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/bjd.14399","article-title":"Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study","volume":"174","author":"Ludbrook","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-37","doi-asserted-by":"publisher","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: A review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_15_2023\/ref-38","doi-asserted-by":"publisher","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.25259\/IJDVL_15_2023\/ref-41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_15_2023\/ref-43","doi-asserted-by":"publisher","first-page":"104499","DOI":"10.1016\/j.amsu.2022.104499","article-title":"FDA approves Ruxolitinib (Opzelura) for Vitiligo Therapy: A breakthrough in the field of dermatology","volume":"81","author":"Sheikh","year":"2022","journal-title":"Ann Med Surg (Lond)"},{"key":"10.25259\/IJDVL_15_2023\/ref-44","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-45","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/09546634.2017.1339013","article-title":"Importance of light in the treatment of vitiligo with JAK-inhibitors","volume":"29","author":"Joshipura","year":"2018","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_15_2023\/ref-47","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/ajd.13572","article-title":"Two cases of vitiligo vulgaris treated with topical Janus kinase inhibitor delgocitinib","volume":"62","author":"Yagi","year":"2021","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-48","first-page":"20","article-title":"A literature review investigating the use of topical janus kinase inhibitors for the treatment of vitiligo","volume":"15","author":"White","year":"2022","journal-title":"J Clin Aesthet Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-49","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1080\/09546634.2020.1735615","article-title":"Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis","volume":"33","author":"Phan","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_15_2023\/ref-50","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-51","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.jaad.2019.04.032","article-title":"A pilot study of 2% tofacitinib cream with narrowband ultraviolet B for the treatment of facial vitiligo","volume":"81","author":"McKesey","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-52","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1159\/000513938","article-title":"Topical tofacitinib: A janus kinase inhibitor for the treatment of vitiligo in an adolescent patient","volume":"13","author":"Berbert Ferreira","year":"2021","journal-title":"Case Rep Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-53","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: A pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-54","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/ajd.13348","article-title":"Repigmentation of vitiligo with oral baricitinib","volume":"61","author":"Mumford","year":"2020","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-55","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.rdc.2009.12.001","article-title":"Cutaneous lupus and the cutaneous lupus erythematosus disease area and severity index instrument","volume":"36","author":"Klein","year":"2010","journal-title":"Rheum Dis Clin North Am"},{"key":"10.25259\/IJDVL_15_2023\/ref-56","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1016\/S0140-6736(14)60128-8","article-title":"Systemic lupus erythematosus","volume":"384","author":"Lisnevskaia","year":"2014","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_15_2023\/ref-57","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/S0140-6736(13)60954-X","article-title":"Immunopathogenic mechanisms of systemic autoimmune disease","volume":"382","author":"Wahren-Herlenius","year":"2013","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_15_2023\/ref-58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-59","first-page":"81:327","article-title":"POS0190\u2005Efficacy and safety of baricitinib in patients with systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, parallel-group, phase 3 studies","author":"Morand","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.25259\/IJDVL_15_2023\/ref-61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2022-eular.5020a","article-title":"LB0004\u2005Efficacy and safety of deucravacitinib, an oral, selective, allosteric TYK2 inhibitor, in patients with active systemic lupus erythematosus: A Phase 2, randomized, double-blind, placebo-controlled study","volume":"81","author":"Morand","year":"2022","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.25259\/IJDVL_15_2023\/ref-65","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","article-title":"Hidradenitis suppurativa","volume":"6","author":"Sabat","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.25259\/IJDVL_15_2023\/ref-66","doi-asserted-by":"publisher","first-page":"932","DOI":"10.2340\/00015555-3012","article-title":"achieving hidradenitis suppurativa response score is associated with significant improvement in clinical and patient-reported outcomes: Post hoc analysis of pooled data from PIONEER I and II","volume":"98","author":"Kimball","year":"2018","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_15_2023\/ref-67","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.1016\/j.jid.2016.04.036","article-title":"Intrinsic defect in keratinocyte function leads to inflammation in hidradenitis suppurativa","volume":"136","author":"Hotz","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-68","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4049\/jimmunol.0903907","article-title":"Deficiency of IL-22 contributes to a chronic inflammatory disease: pathogenetic mechanisms in acne inversa","volume":"186","author":"Wolk","year":"2011","journal-title":"J Immunol"},{"key":"10.25259\/IJDVL_15_2023\/ref-69","doi-asserted-by":"publisher","first-page":"2488","DOI":"10.1111\/jdv.18465","article-title":"Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa","volume":"36","author":"Frings","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_15_2023\/ref-70","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdcr.2019.10.010","article-title":"Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients","volume":"6","author":"Savage","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_15_2023\/ref-71","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","article-title":"Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies","volume":"186","author":"Alavi","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-72","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/bjd.21297","article-title":"Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox","volume":"186","author":"Sibbald","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-73","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1007\/s40265-021-01566-2","article-title":"Clinical implementation of biologics and small molecules in the treatment of hidradenitis suppurativa","volume":"81","author":"Aarts","year":"2021","journal-title":"Drugs"},{"key":"10.25259\/IJDVL_15_2023\/ref-77","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.clindermatol.2006.07.001","article-title":"Dermatomyositis","volume":"24","author":"Callen","year":"2006","journal-title":"Clin Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-78","first-page":"438","article-title":"Dermatomyositis and polymyositis associated with malignancy: a 21-year retrospective study","volume":"35","author":"Andr\u00e1s","year":"2008","journal-title":"J Rheumatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-79","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1212\/wnl.59.8.1170","article-title":"Molecular profiles of inflammatory myopathies","volume":"59","author":"Greenberg","year":"2002","journal-title":"Neurology"},{"key":"10.25259\/IJDVL_15_2023\/ref-80","doi-asserted-by":"publisher","first-page":"e14939","DOI":"10.1111\/dth.14939","article-title":"JAK-inhibitors for dermatomyositis: A concise literature review","volume":"34","author":"Paudyal","year":"2021","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_15_2023\/ref-81","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: An open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-82","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.semarthrit.2016.08.009","article-title":"A case of refractory dermatomyositis responsive to tofacitinib","volume":"46","author":"Paik","year":"2017","journal-title":"Semin Arthritis Rheum"},{"key":"10.25259\/IJDVL_15_2023\/ref-83","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: An alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-84","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1056\/NEJMc1412997","article-title":"Remission of recalcitrant dermatomyositis treated with ruxolitinib","volume":"371","author":"Hornung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_15_2023\/ref-89","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2022.2116926","article-title":"JAK inhibitors in lichen planus: a review of pathogenesis and treatments [published online ahead of print, 2022 Aug 29]","author":"Motamed-Sanaye","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"10.25259\/IJDVL_15_2023\/ref-90","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1016\/j.jaci.2020.01.031","article-title":"Treatment of severe lichen planus with the JAK inhibitor tofacitinib","volume":"145","author":"Damsky","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_15_2023\/ref-91","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/j.jid.2022.01.015","article-title":"Ruxolitinib cream in the treatment of cutaneous lichen planus: a prospective, open-label study","volume":"142","author":"Brumfiel","year":"2022","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-92","doi-asserted-by":"publisher","first-page":"e12656","DOI":"10.1111\/dth.12656","article-title":"Tofacitinib for the treatment of lichen planopilaris: A case series","volume":"31","author":"Yang","year":"2018","journal-title":"Dermatol Ther"},{"key":"10.25259\/IJDVL_15_2023\/ref-93","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1067\/mjd.2001.114596","article-title":"Sarcoidosis","volume":"44","author":"English","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-94","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1378\/chest.08-1527","article-title":"Sarcoidosis of the skin: a review for the pulmonologist","volume":"136","author":"Lodha","year":"2009","journal-title":"Chest"},{"key":"10.25259\/IJDVL_15_2023\/ref-95","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3389\/fimmu.2020.01443","article-title":"Biomarkers in the diagnosis and prognosis of sarcoidosis: current use and future prospects","volume":"11","author":"Kraaijvanger","year":"2020","journal-title":"Front Immunol"},{"key":"10.25259\/IJDVL_15_2023\/ref-96","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.jdcr.2021.08.012","article-title":"Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis","volume":"16","author":"Talty","year":"2021","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_15_2023\/ref-97","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1056\/NEJMoa1805958","article-title":"Tofacitinib treatment and molecular analysis of cutaneous sarcoidosis","volume":"379","author":"Damsky","year":"2018","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_15_2023\/ref-98","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-99","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jaad.2020.10.016","article-title":"Tofacitinib for cutaneous and pulmonary sarcoidosis: A case series","volume":"84","author":"Kerkemeyer","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-100","doi-asserted-by":"publisher","first-page":"1801482","DOI":"10.1183\/13993003.01482-2018","article-title":"Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia","volume":"52","author":"Rotenberg","year":"2018","journal-title":"Eur Respir J"},{"key":"10.25259\/IJDVL_15_2023\/ref-101","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jdcr.2019.02.006","article-title":"Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera","volume":"5","author":"Wei","year":"2019","journal-title":"JAAD Case Rep."},{"key":"10.25259\/IJDVL_15_2023\/ref-102","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1136\/annrheumdis-2020-217271","article-title":"Steroid-resistant sarcoidosis treated with baricitinib","volume":"79","author":"Scheinberg","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.25259\/IJDVL_15_2023\/ref-103","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.1038\/s41467-022-30615-x","article-title":"Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis","volume":"13","author":"Damsky","year":"2022","journal-title":"Nat Commun"},{"key":"10.25259\/IJDVL_15_2023\/ref-104","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.iac.2009.10.001","article-title":"Pathogenesis and management of graft-versus-host disease","volume":"30","author":"Choi","year":"2010","journal-title":"Immunol Allergy Clin North Am"},{"key":"10.25259\/IJDVL_15_2023\/ref-105","doi-asserted-by":"publisher","first-page":"515.e1","DOI":"10.1016\/j.jaad.2011.11.960","article-title":"Graft-versus-host disease: Part I","volume":"66","author":"Hymes","year":"2012","journal-title":"Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_15_2023\/ref-106","doi-asserted-by":"publisher","first-page":"2040620720914489","DOI":"10.1177\/2040620720914489","article-title":"Insights into the role of the JAK\/STAT signaling pathway in graft-versus-host disease","volume":"11","author":"Abboud","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.25259\/IJDVL_15_2023\/ref-107","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.25259\/IJDVL_15_2023\/ref-108","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oncolo\/oyac042","article-title":"FDA approval summary: ruxolitinib for treatment of chronic graft-versus-host disease after failure of one or two lines of systemic therapy","volume":"27","author":"Le","year":"2022","journal-title":"Oncologist"},{"key":"10.25259\/IJDVL_15_2023\/ref-109","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-140392","article-title":"Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): Preliminary analysis results of a phase 1\/2 study","volume":"136","author":"Holtzman","year":"2020","journal-title":"Blood"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-in-dermatology-a-review-of-their-use-in-psoriasis-vitiligo-systemic-lupus-erythematosus-hidradenitis-suppurativa-dermatomyositis-lichen-planus-lichen-planopilaris-sarco\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-in-dermatology-a-review-of-their-use-in-psoriasis-vitiligo-systemic-lupus-erythematosus-hidradenitis-suppurativa-dermatomyositis-lichen-planus-lichen-planopilaris-sarco\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T15:10:26Z","timestamp":1703430626000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/janus-kinase-inhibitors-in-dermatology-a-review-of-their-use-in-psoriasis-vitiligo-systemic-lupus-erythematosus-hidradenitis-suppurativa-dermatomyositis-lichen-planus-lichen-planopilaris-sarco\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,5]]},"references-count":88,"alternative-id":["10.25259\/IJDVL_15_2023"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_15_2023","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,5]]},"article-number":"30"}}